Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin

NCT07815704 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT07815704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07815704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
August 31, 2031
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancers, high grade serous adenocarcinoma of ovary, ovarian cancer, primary peritoneal cancer